Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

PLoS Medicine

Volumn 3, Issue 6, 2006, Pages 0865-0873

  Sullivan, Nancy J ^a   Geisbert, Thomas W ^b   Geisbert, Joan B ^b   Shedlock, Devon J ^a   Xu, Ling ^a   Lamoreaux, Laurie ^a   Custers, Jerome H H V ^c   Popernack, Paul M ^a   Yang, Zhi Yong ^a   Pau, Maria G ^c   Roederer, Mario ^a   Koup, Richard A ^a   Goudsmit, Jaap ^c   Jahrling, Peter B ^a   Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; EBOLA VACCINE; MUTANT PROTEIN; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; NUCLEOPROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; EBOLA VIRUS; GENE DELETION; IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; LOW DRUG DOSE; MACACA; NONHUMAN; POINT MUTATION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS STRAIN; ADENOVIRUS; ANIMAL; CELL LINE; DOSE RESPONSE; EBOLA HEMORRHAGIC FEVER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; MACACA FASCICULARIS; MUTATION; PATHOGENICITY; VACCINATION;

ADENOVIRIDAE; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EBOLA VACCINES; EBOLAVIRUS; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA FASCICULARIS; MUTATION; NUCLEOPROTEINS; TRANSFECTION; VACCINATION; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

EID: 33745339304     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030177     Document Type: Article

References (26)

1. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, et al. (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5: 423-426.
2. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408: 605-609.
3. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424: 681-684.
4. Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, et al. (1998) Immunization for Ebola virus infection. Nat Med 4: 37-42.
5. Wilson JA, Hart MK (2001) Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 75: 2660-2664.
6. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, et al. (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9: 1909-1917.
7. Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, et al. (2001) Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 75: 3335-3342.
8. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, et al. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 8: 453-465.
9. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, van Ormondt H, et al. (1996) Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 7: 215-222.
10. Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, et al. (1996) An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 7: 1205-1217.
11. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals. 6th Revision. Washington (D. C.): National Research Council, National Academy Press.
12. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, et al. (1996) Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 11: 135-140.
13. Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, et al. (2004) pH-dependent entry of Severe Acute Respiratory Syndrome coronavirus is mediated by the Spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 78: 5642-5650.
14. Waldrop SL, Davis KA, Maino VC, Picker LJ (1998) Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol 161: 5284-5295.
15. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, et al. (2000) Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6: 886-889.
16. Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, et al. (2005) Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol 79: 547-553.
17. Takada A, Watanabe S, Ito H, Okazaki K, Kida H, et al. (2000) Downregulation of b1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278: 20-26.
18. Chan SY, Ma MC, Goldsmith MA (2000) Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol 81: 2155-2159.
19. Volchkov VE, Becker S, Volchkova VA, Ternovoj VA, Kotov AN, et al. (1995) GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214: 421-430.
20. Sanchez A, Yang Z, Xu L, Nabel GJ, Crews T, et al. (1998) Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 72: 6442-6447.
21. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163: 2347-2370.
22. Manicassamy B, Wang J, Jiang H, Rong L (2005) Comprehensive analysis of ebola virus GP1 in viral entry. J Virol 79: 4793-4805.
23. Cao J, Park IW, Cooper A, Sodroski J (1996) Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1. J Virol 70: 1340-1354.
24. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11: 786-790.
25. Prevots DR, Burr RK, Sutter RW, Murphy TV (2000) Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49: 1-22.
26. Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, et al. (2005) Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 79: 14161-14168.